top of page

Eisai bewildered as IQWIG fails to recognise OS benefit of liposarcoma drug

The German Institute for Quality and Efficiency in Health Care (IQWiG) has published a report which suggests that on formal or methodological grounds, respectively, no additional benefit has been proven for halaven (eribulin) versus established comparator therapies – as defined by the Federal Joint Committee (G-BA) – for the treatment of unresectable advanced or metastatic liposarcomas.

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page